Multi-Gene Assays Now Recommended To Refine Chemotherapy Decisions in Breast Cancer

11th Annual Palm Beach Cancer Symposium (April 3-4, 2009 Hollywood, Florida)—Peter Goodwin interviews Kathy Albain, Professor of Medicine at Loyola University, Chicago, on her return from the 2009 St Gallen consensus meeting which formulated updated recommendations about adjuvant therapy for breast cancer. The 21 gene recurrence score and the 70-gene profiling assay have now been endorsed by this Swiss meeting as significant contributors to the decision making process on cytotoxic chemotherapy for patients with estrogen receptor positive disease, including both node negative and node positive early breast cancer.